Atorvastatin and simvastatin in clinical management of high-risk patients
Aim. То assess the use of average therapeutic doses of atorvastatin and simvastatin (Torvacard and Simvacard) in real-world clinical management of high-risk patients.Material and methods. The study included 347 doctors from 30 Russian cities and 1163 high-risk patients randomised into two groups: To...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1152 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250789441142784 |
|---|---|
| author | S. A. Shalnova A. D. Deev |
| author_facet | S. A. Shalnova A. D. Deev |
| author_sort | S. A. Shalnova |
| collection | DOAJ |
| description | Aim. То assess the use of average therapeutic doses of atorvastatin and simvastatin (Torvacard and Simvacard) in real-world clinical management of high-risk patients.Material and methods. The study included 347 doctors from 30 Russian cities and 1163 high-risk patients randomised into two groups: Torvacard, 20 mg/day (n=672) and Simvacard, 20 mg/day (n=491). Ah patients completed a standard questionnaire, underwent anthropometry and measurement of blood pressure, heart rate, total cholesterol (TCH), low and high-density lipoprotein CH(LDL-CH, HDL-CH), triglycerides (TG), as well as liver enzymes and creatine phosphokinase activity as safety markers. The study lasted for 3 months. Lipid-lowering therapy was regarded as effective if target TDT-CH levels (<2,5 mmol/1) were achieved.Results. TCH and LDL-CH levels reduced by 31,2% and 38,8%, respectively, in Torvacard group, and by 21,4% and 21,5% in Simvacard group (p<0,001). Both medications significantly reduced TG levels — by 21,1% and 15,9%, respectively. In Torvacard group, more than 50% of the patients achieved target LDL-CH levels, and in Simvacard group — only 19,6% (p<0,0001). In total, 18 adverse events were registered: 10 (1,5%) and 8 (1,5%) in Torvacard and Simvacard groups, respectively (p=0,9).Conclusion. Early administration of a higher Torvacard dose (20 mg) was much more effective in achieving target lipid levels in high-risk patients, without increasing adverse event risk. Clinicians should remember about the positive correlation between statin dose and adverse effect risk, monitoring chnical and laboratory safety parameters. |
| format | Article |
| id | doaj-art-9ddc4fe10803401590166c7cfa7dbb23 |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2009-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-9ddc4fe10803401590166c7cfa7dbb232025-08-20T03:57:09Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-02-01816266864Atorvastatin and simvastatin in clinical management of high-risk patientsS. A. Shalnova0A. D. Deev1State Research Centre for Preventive MedicineState Research Centre for Preventive MedicineAim. То assess the use of average therapeutic doses of atorvastatin and simvastatin (Torvacard and Simvacard) in real-world clinical management of high-risk patients.Material and methods. The study included 347 doctors from 30 Russian cities and 1163 high-risk patients randomised into two groups: Torvacard, 20 mg/day (n=672) and Simvacard, 20 mg/day (n=491). Ah patients completed a standard questionnaire, underwent anthropometry and measurement of blood pressure, heart rate, total cholesterol (TCH), low and high-density lipoprotein CH(LDL-CH, HDL-CH), triglycerides (TG), as well as liver enzymes and creatine phosphokinase activity as safety markers. The study lasted for 3 months. Lipid-lowering therapy was regarded as effective if target TDT-CH levels (<2,5 mmol/1) were achieved.Results. TCH and LDL-CH levels reduced by 31,2% and 38,8%, respectively, in Torvacard group, and by 21,4% and 21,5% in Simvacard group (p<0,001). Both medications significantly reduced TG levels — by 21,1% and 15,9%, respectively. In Torvacard group, more than 50% of the patients achieved target LDL-CH levels, and in Simvacard group — only 19,6% (p<0,0001). In total, 18 adverse events were registered: 10 (1,5%) and 8 (1,5%) in Torvacard and Simvacard groups, respectively (p=0,9).Conclusion. Early administration of a higher Torvacard dose (20 mg) was much more effective in achieving target lipid levels in high-risk patients, without increasing adverse event risk. Clinicians should remember about the positive correlation between statin dose and adverse effect risk, monitoring chnical and laboratory safety parameters.https://cardiovascular.elpub.ru/jour/article/view/1152high-risk patientsstatinstherapy effectivenessachieving target levels of low-density lipoprotein cholesterol |
| spellingShingle | S. A. Shalnova A. D. Deev Atorvastatin and simvastatin in clinical management of high-risk patients Кардиоваскулярная терапия и профилактика high-risk patients statins therapy effectiveness achieving target levels of low-density lipoprotein cholesterol |
| title | Atorvastatin and simvastatin in clinical management of high-risk patients |
| title_full | Atorvastatin and simvastatin in clinical management of high-risk patients |
| title_fullStr | Atorvastatin and simvastatin in clinical management of high-risk patients |
| title_full_unstemmed | Atorvastatin and simvastatin in clinical management of high-risk patients |
| title_short | Atorvastatin and simvastatin in clinical management of high-risk patients |
| title_sort | atorvastatin and simvastatin in clinical management of high risk patients |
| topic | high-risk patients statins therapy effectiveness achieving target levels of low-density lipoprotein cholesterol |
| url | https://cardiovascular.elpub.ru/jour/article/view/1152 |
| work_keys_str_mv | AT sashalnova atorvastatinandsimvastatininclinicalmanagementofhighriskpatients AT addeev atorvastatinandsimvastatininclinicalmanagementofhighriskpatients |